Rilmakalim

DB19913ExperimentalSmall molecule

Rilmakalim is a small molecule drug. The usage of the INN stem '-kalim' in the name indicates that Rilmakalim is a potassium channel activator, antihypertensive. Rilmakalim has a monoisotopic molecular...

Mechanism: Pharmacologically active on ATP-sensitive potassium channel
Curator reviewed
Formula / weight: C₂₁H₂₃NO₅S · 401.48 g/mol (avg)

Resolves to

Compound

UNII47Y56T6LEICAS132014-21-2ChEMBLCHEMBL275758ChEBI747959PubChem65966

Structure

InChIKeyLKAQWOWWTKFLNX-UXHICEINSA-NSMILESCC1(C)OC2=CC=C(C=C2[C@H]([C@@H]1O)N1CCCC1=O)S(=O)(=O)C1=CC=CC=C1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Rilmakalim, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account